Last reviewed · How we verify
Sanorex (MAZINDOL)
Sanorex (MAZINDOL) is a small molecule drug that targets the sodium-dependent noradrenaline transporter. Originally developed and currently owned by Novartis, it was FDA-approved in 1973 for the treatment of obesity. As an off-patent medication with no active Orange Book patents, Sanorex is available as a branded product. Key safety considerations include its potential impact on blood pressure and heart rate. Sanorex is a non-stimulant medication that works by increasing the levels of norepinephrine in the brain, which helps to suppress appetite and increase feelings of fullness.
At a glance
| Generic name | MAZINDOL |
|---|---|
| Sponsor | Novartis |
| Drug class | mazindol |
| Target | Sodium-dependent noradrenaline transporter |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Obesity
Common side effects
Drug interactions
- Ioflupane I-123
Key clinical trials
- A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 (PHASE3)
- An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy (PHASE2)
- Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy (PHASE2)
- Mazindol for Cocaine Abuse - 2 (PHASE2)
- Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD) (PHASE2)
- Mazindol in Children With ADHD : Open-label, Efficacy, Safety and Pharmacokinetic Pilot Trial
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sanorex CI brief — competitive landscape report
- Sanorex updates RSS · CI watch RSS